Literature DB >> 7084068

[Clinical relevance of immunoglobulin M antibody fraction against hepatitis B core antigen (anti-HBc-IgM) (author's transl)].

A Feuerhake, E Wille, R Müller.   

Abstract

Forty-four anti-HBc positive patients with various liver diseases were followed up over 2-3 years with enzyme-immunological determinations of the IgM fraction of anti HBc (anti-HBc-IgM). Patients with acute virus hepatitis B (n = 10) had anti-HBc-IgM titres greater than or equal to 10(-3) in the acute phase. In the reconvalescent phase the titre decreased significantly but was still detectable at a level of 10(-1) two years after the onset of the disease. In patients with HBs-antigen positive chronic active hepatitis (n = 25) the anti-HBc-IgM was always detectable when HBe-antigen was positive. Patients with HBe-antigen negative chronic active hepatitis B showed various anti-HBc-IgM findings. Patients with liver diseases not due to hepatitis B virus infections (n = 9) were always anti-HBc-IgM negative. Thus with the help of anti-HBc-IgM determinations acute hepatitis B virus infection can be diagnosed in HBs-antigen negative people. On the other hand it is not suitable for differentiation between acute and chronic hepatitis B infections in HBs-antigen positive persons.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7084068     DOI: 10.1055/s-2008-1070064

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

Review 1.  The humoral immune response in acute and chronic hepatitis B virus infection.

Authors:  D R Milich; M Sallberg; T Maruyama
Journal:  Springer Semin Immunopathol       Date:  1995

2.  Absence of circulating HBsAg in acute hepatitis B.

Authors:  J Fasel-Felley; R Peitrequin; P C Frei
Journal:  Infection       Date:  1984 May-Jun       Impact factor: 3.553

3.  Cutoff levels of immunoglobulin M antibody against viral core antigen for differentiation of acute, chronic, and past hepatitis B virus infections.

Authors:  W H Gerlich; A Uy; F Lambrecht; R Thomssen
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.